RE: Change your subject heading13 Feb 2019 19:31
Using a 90% probability of approval and a 15% discount rate leads to a net present value for iclaprim in ABSSSI of $475 million. After factoring in the company’s cash position, potential cash from the exercise of outstanding warrants, estimated capital requirements, and dividing by the fully diluted ADS share count of 17.0 million leads to a valuation of $28 per share. The stock continues to trade at a significant discount to our valuation, thus offering investors plenty of upside at the current price. That’s almost 3 times what it’s currently trading at.